Hematologic Diseases

175 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.

Narrower: Anemia 43, Anemia, Aplastic 5, Anemia, Refractory, with Excess of Blasts 12, Anemia, Sickle Cell 13, Antithrombin III Deficiency 1, beta-Thalassemia 3, Bone Marrow Failure Disorders 9, Congenital Bone Marrow Failure Syndromes 3, Cytopenia 9, Factor VII Deficiency 1, Febrile Neutropenia 2, GATA2 Deficiency 2, Hemoglobinopathies 19, Hemoglobinuria, Paroxysmal 3, Hemophilia A 14, Hemophilia B 6, Hypereosinophilic Syndrome 2, Myelodysplastic Syndromes 78, Myelodysplastic-Myeloproliferative Diseases 3, Myeloproliferative Disorders 17, Primary Myelofibrosis 10, Purpura 2, Purpura, Thrombotic Thrombocytopenic 1, Telangiectasia, Hereditary Hemorrhagic 2, Thrombocythemia, Essential 3, Thrombocytopenia 5, Vaso-Occlusive Crises 1, von Willebrand Disease, Type 3 3, von Willebrand Diseases 4

Treatments and conditions

Hematologic Diseases
Treatment and conditionWhere it standsTrials
AAV2/8-HLP-FVIII-V3 for hemophilia aPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
AB-8939 for gata2 deficiencyPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Abatacept for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Albipagrastim alf for febrile neutropeniaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
ALEMTUZUMAB + Cyclophosphamide + FLUDARABINE for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ALEMTUZUMAB + Cyclophosphamide + FLUDARABINE + Melphalan for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
allogeneic hematopoietic stem cell transplantation + Pharmacological Study + CLOFARABINE + Melphalan + Sirolimus + Tacrolimus for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ANB-010, dose 1 for hemophilia aPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
ANB-010, dose 2 for hemophilia aPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
ANB-010, dose 3 for hemophilia aPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Antithrombin iii human for antithrombin iii deficiencyPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ascorbic Acid for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)2
Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn + G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn + G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Aspirin for purpura, thrombotic thrombocytopenicTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
ASTX727 for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ATIR101 + T-cell depleted HSCT from a related, haploidentical donor for myelodysplastic syndromesTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
ATO + Ascorbic acid for myelodysplastic syndromesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Atorvastatin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Autologous testicular tissue transplantation of prepubertal frozen testicular tissue for hematologic diseasesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Azacitidine for anemiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Azacitidine for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Azacitidine for thrombocytopeniaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Azacitidine + Ascorbic Acid for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Azacitidine + Ascorbic Acid for myeloproliferative disordersPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Azacitidine + ENASIDENIB MESYLATE for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Azacitidine + Venetoclax + Mobinitinib for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
AZD3632 for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
AZD3632 + Posaconazole for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Benralizumab for hypereosinophilic syndromePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Benserazide Only Product for anemia, sickle cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Benserazide Only Product for beta-thalassemiaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Bezuclastinib for myeloproliferative disordersPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biospecimen Collection + Bone Marrow Aspiration + Olaparib for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
BMS-986470 for anemia, sickle cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
BMS-986470 + Famotidine + PANTOPRAZOLE for anemia, sickle cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
BMS-986470 + Placebo for anemia, sickle cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
BPA prophylaxis + Factor (FVIII or FIX) prophylaxis + FITUSIRAN for hemophilia aPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Brentuximab vedotin for hematologic diseasesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CID-103 for purpuraPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
CIPROFLOXACIN + Ceftazidime for febrile neutropeniaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CliniMACS + G-CSF + HPC,A Infusion + RITUXIMAB + BLINATUMOMAB + Cyclophosphamide + THIOTEPA + LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN + Mesna + FLUDARABINE + Melphalan + Sirolimus + Tacrolimus for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
CliniMacs TCR alpha-beta-Biotin system for myelodysplastic syndromesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Clotting factor concentrates (CFC) or bypassing agents (BPA) + EMICIZUMAB + FITUSIRAN + ANTITHROMBIN III HUMAN for hemophilia aPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Clotting factor concentrates (CFC) or bypassing agents (BPA) + FITUSIRAN + ANTITHROMBIN III HUMAN for hemophilia aPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
CREADY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth) for anemia, sickle cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Crizanlizumab for anemia, sickle cellTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CSL222 (AAV5-hFIXco-Padua) for hemophilia bPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
CSL222 (Adeno-associated viral vector serotype 5 [AAV5]-hFIXco-Padua) for hemophilia bPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cyclophosphamide for anemia, refractory, with excess of blastsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cyclophosphamide for myelodysplastic syndromesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CYTARABINE + Cladribine + Azacitidine + Venetoclax for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Danicopan for hemoglobinuria, paroxysmalPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Darbepoetin alfa + canakinumab for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Decitabine + ARSENIC TRIOXIDE for myelodysplastic syndromesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Decitabine + QUIZARTINIB + Venetoclax for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
DIAG723 for telangiectasia, hereditary hemorrhagicPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Donor Leukocyte Infusion (DLI) + INTERFERON GAMMA-1B for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Donor mobilized PBSC infusion + G-CSF + RITUXIMAB + Cyclophosphamide + MP + FLUDARABINE for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Donor mobilized PBSC infusion + G-CSF + Total Body Irradiation (TBI) (Plan 1) + RITUXIMAB + Cyclophosphamide + MP + FLUDARABINE for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Echocardiography + Electrocardiogram (ECG) + DEFERIPRONE + Deferoxamine + Deferasirox for anemia, sickle cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
EDIT-301 for anemia, sickle cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
efanesoctocog alfa (BIVV001) for hemophilia aPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Elritercept for anemiaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Elritercept for myelodysplastic syndromesPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Exagamglogene autotemcel for anemia, sickle cellPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)5
Exagamglogene autotemcel for beta-thalassemiaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Exerenibart for beta-thalassemiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Fidanacogene Elaparvovec for hemophilia aPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Fidanacogene Elaparvovec for hemophilia bPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
Fitusiran for hemophilia aPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)4
Fitusiran for hemophilia bPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + Mitoxantrone + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + SORAFENIB + Mitoxantrone + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Mitoxantrone + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + SORAFENIB + Mitoxantrone + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
G-CSF + ITMHA + Stem Cell Transplant + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
G-CSF + ITMHA + Stem Cell Transplant + CYTARABINE + Dexrazoxane + ETOPOSIDE + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Givinostat for primary myelofibrosisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Givinostat for thrombocythemia, essentialTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Granulocyte Colony-Stimulating Factor (G-CSF) + MGTA 456 Infusion + Busulfan + FLUDARABINE + Melphalan + Mycophenolate Mofetil Hydrochloride for anemia, refractory, with excess of blastsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Granulocyte Colony-Stimulating Factor (G-CSF) + MGTA 456 Infusion + Total Body Irradiation (TBI) + Cyclophosphamide + FLUDARABINE + Mycophenolate Mofetil Hydrochloride + Tacrolimus for anemia, refractory, with excess of blastsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
GVHD prophylaxis regimen + RIC regimen for anemia, sickle cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GVHD prophylaxis regimen + RIC regimen for bone marrow failure disordersPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Hematopoietic stem-cell transplantation for myelodysplastic syndromesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
HMB-002 (Part A) for von willebrand disease, type 3Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
HMB-002 (Part B) for von willebrand disease, type 3Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
HMB-002 with Concomitant Factor Concentrate (Part C) (Not Applicable in US) for von willebrand disease, type 3Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Hydroxycarbamide for anemia, sickle cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Iloprost for vaso-occlusive crisesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Imatinib Mesylate for hypereosinophilic syndromeTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Immediate HSCT Group for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Iron sucrose for anemiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Isatuximab for anemia, aplasticPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + CYTARABINE + ASPARAGINASE ERWINIA CHRYSANTHEMI + ASPARAGINASE + Mitoxantrone Hydrochloride for myelodysplastic syndromesPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + CYTARABINE + ASPARAGINASE ERWINIA CHRYSANTHEMI + ASPARAGINASE + Mitoxantrone Hydrochloride for myeloproliferative disordersPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + CYTARABINE + ETOPOSIDE + THIOGUANINE + Daunorubicin Hydrochloride for myelodysplastic syndromesPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + CYTARABINE + ETOPOSIDE + THIOGUANINE + Daunorubicin Hydrochloride for myeloproliferative disordersPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Luspatercept for anemiaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
Luspatercept for myelodysplastic syndromesPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Luspatercept for primary myelofibrosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Lusutrombopag combined with recombinant human thrombopoietin for thrombocytopeniaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Marstacimab for hemophilia aPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Marstacimab for hemophilia bPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Mitapivat for anemiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Mobilized CD34-selected Peripheral Blood Stem Cell graft for anemia, refractory, with excess of blastsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Mobinitinib for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Momelotinib for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Navitoclax for primary myelofibrosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nintedanib for telangiectasia, hereditary hemorrhagicPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nk-dli for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Peginterferon α-2b injection for thrombocythemia, essentialPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pelabresib for primary myelofibrosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Peripheral Blood Hematopoietic Cell Transplantation (HCT) + Total body irradiation (TBI) + Cyclophosphamide + Busulfan + FLUDARABINE + FILGRASTIM + Mycophenolate Mofetil Hydrochloride + Sirolimus for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Peripheral Blood Hematopoietic Cell Transplantation (HCT) + Total body irradiation (TBI) + Cyclophosphamide + Busulfan + FLUDARABINE + FILGRASTIM + Mycophenolate Mofetil Hydrochloride + Sirolimus for primary myelofibrosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Peripheral Blood Stem Cell Transplantation + Hematopoietic Cell Transplantation + Laboratory Biomarker Analysis + Quality-of-Life Assessment + FLUDARABINE PHOSPHATE + Cyclophosphamide + Mycophenolate Mofetil + Busulfan + Tacrolimus for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 1 Dose Level 1 + Phase 1 Dose Level 2 + Phase 1 Dose Level 3 for anemia, refractory, with excess of blastsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 1 Dose Level 1 + Phase 1 Dose Level 2 + Phase 1 Dose Level 3 for congenital bone marrow failure syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 1 Dose Level 1 + Phase 1 Dose Level 2 + Phase 1 Dose Level 3 for hemoglobinopathiesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 2 Established Dose from prior study, NCT03810196 for anemia, refractory, with excess of blastsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 2 Established Dose from prior study, NCT03810196 for congenital bone marrow failure syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 2 Established Dose from prior study, NCT03810196 for hemoglobinopathiesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 2 Maximum Tolerated Dose determined in Phase 1 for anemia, refractory, with excess of blastsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 2 Maximum Tolerated Dose determined in Phase 1 for congenital bone marrow failure syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 2 Maximum Tolerated Dose determined in Phase 1 for hemoglobinopathiesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo for Oral Azacitidine for anemiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo for Oral Azacitidine for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo for Oral Azacitidine for thrombocytopeniaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pozelimab + cemdisiran for hemoglobinuria, paroxysmalPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton Total Marrow Irradiation for anemia, refractory, with excess of blastsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
reduced-dose conditioning regimen containing TBI in hematopoietic stem cell transplantation treating elderly patients with aplastic anemia for anemia, aplasticTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
RITUXIMAB + Cyclophosphamide + MP + Busulfan + FLUDARABINE for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Rivogenlecleucel + rimiducid for anemia, aplasticTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Rivogenlecleucel + rimiducid for cytopeniaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Rivogenlecleucel + rimiducid for myelodysplastic syndromesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Romiplostim for anemia, aplasticPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Romiplostim for anemia, refractory, with excess of blastsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ROPEGINTERFERON ALFA-2B for thrombocythemia, essentialPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Rosuvastatin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ruxolitinib for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ruxolitinib + NAVITOCLAX for primary myelofibrosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ruxoprubart for hemoglobinuria, paroxysmalTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Selinexor for primary myelofibrosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sonrotoclax for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sonrotoclax for myelodysplastic-myeloproliferative diseasesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sonrotoclax + Azacitidine for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sonrotoclax + Azacitidine for myelodysplastic-myeloproliferative diseasesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sonrotoclax + Posaconazole + Azacitidine for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sonrotoclax + Posaconazole + Azacitidine for myelodysplastic-myeloproliferative diseasesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
SPK-8011QQ for hemophilia aPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
SR604 for factor vii deficiencyPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)2
SR604 for hemophilia aPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
SR604 for hemophilia bPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
SR604 for von willebrand diseasesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Stem Cell Infusion + Total Body Irradiation + Cyclophosphamide + Mycophenolate Mofetil + TREOSULFAN + FLUDARABINE + Tacrolimus for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tasquinimod for primary myelofibrosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
TASQUINIMOD + Ruxolitinib for primary myelofibrosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
TCRα/β+ and CD19+ depleted haploidentical stem cell transplantation for anemia, sickle cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
thrombopoietin receptor agonist (TPO-RA) + Cyclosporine + ROMIPLOSTIM for anemia, aplasticTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Total-Body Irradiation + Umbilical Cord Blood Transplantation + Cyclophosphamide + DILANUBICEL + FLUDARABINE for anemia, refractory, with excess of blastsTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Total-Body Irradiation + Umbilical Cord Blood Transplantation + Cyclophosphamide + THIOTEPA + DILANUBICEL + FLUDARABINE for anemia, refractory, with excess of blastsTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Tranexamic acid for anemiaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tretinoin for thrombocytopeniaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ULIXERTINIB + Ruxolitinib for primary myelofibrosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Unmanipulated Bone Marrow Graft with Cyclophosphamide + Cyclophosphamide for anemia, refractory, with excess of blastsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Venetoclax + AB-8939 for gata2 deficiencyPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Venetoclax + FLUDARABINE for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Vitamin C (ascorbic acid) for cytopeniaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Vitamin C (ascorbic acid) for myelodysplastic syndromesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Zemocimig for hemophilia aPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1

Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.